RORγt inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat severe asthma

Table 1 Characteristics of asthma patients and healthy control subjects

	Healthy controls	Severe asthma
N	8	25
Gender (M/F)	3/5	10/15
Age (years)	23 (21–39)	51 (17–66)
Inhaled CS (yes/no/unknown)	0/8/0	25/0/0
Oral CS (yes/no/unknown)	0/8/0	25/0/0
LABA (yes/no/unknown)	0/8/0	24/1/0
SABA (yes/no/unknown)	0/8/0	21/4/0
FEV1% predicted	98.1 (72.1–116.4)	65.6 (32.4–93.8)
Smokers (yes/ex/never/unknown)	0/0/8/0	1/12/8/4
Number of biopsies	13	25
Number of biopsies with IL-17 positive cells (%)	6 (46%)	15 (60%)

A single biopsy was taken from 25 severe asthma patients (N = 25 total) whereas a single biopsy was taken from 3 healthy volunteers and a double biopsy taken from a further 5 healthy volunteers (N = 13 total)
CS corticosteroids, LABA long acting beta-agonist, SABA short acting beta-agonist, FEV₁ forced expiratory volume in 1 min

ISSN: 1465-993X